Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 17/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | INSR | P06213 | 1/20 | 0.44 |
| ▸ | NPM1 | P06748 | 1/20 | 0.44 |
| ▸ | BCR | P11274 | 1/20 | 0.44 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2673192 | 0.87 | MET (0.69) | MET | |
| SCHEMBL4402540 | 0.86 | MET (0.66) | MET | |
| SCHEMBL2672926 | 0.85 | MET (0.65) | METKDM4EKMT2A | |
| SCHEMBL2672884 | 0.85 | MET (0.84) | MET | |
| SCHEMBL4135010 | 0.85 | MET (0.62) | MET | |
| SCHEMBL2672911 | 0.85 | MET (0.64) | MET | |
| SCHEMBL2672413 | 0.85 | MET (0.73) | MET | |
| SCHEMBL13247076 | 0.84 | MET (0.63) | METKDM4EKMT2A | |
| SCHEMBL2673141 | 0.83 | MET (0.80) | MET | |
| SCHEMBL2674011 | 0.82 | MET (0.62) | MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173653-B2 | Pyridiazinone derivatives for the treatment of tumours | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2012-05-08 | — | — | US | disclosed |
| US-8173653-B2 | Pyridiazinone derivatives for the treatment of tumours | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2012-05-08 | — | — | US | disclosed |
| EP-1960370-B1 | PYRIDIAZINONE DERIVATIVES FOR TUMOUR TREATMENT | MERCK PATENT GMBH (DE) | 2011-10-05 | — | — | EP | disclosed |
| US-20080293719-A1 | Pyridiazinone Derivatives for the Treatment of Tumours | MERCK PATENT GESELLSCHAFT (DE) | 2008-11-27 | — | — | US | disclosed |
| US-20080293719-A1 | Pyridiazinone Derivatives for the Treatment of Tumours | MERCK PATENT GESELLSCHAFT (DE) | 2008-11-27 | — | — | US | disclosed |
| WO-2007065518-A1 | PYRIDIAZINONE DERIVATIVES FOR TUMOUR TREATMENT | MERCK PATENT GMBH (DE) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293719-A1 | Pyridiazinone Derivatives for the Treatment of Tumours | MET, RET, ERBB2 | MET 1/4885KDM4E 1695/4885MEN1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.